IntelliPharmaCeutics International (IntelliPharmaCeutics International) Additional Paid-In Capital : $45.10 Mil(As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Additional Paid-In Capital?

IntelliPharmaCeutics International's quarterly additional paid-in capital stayed the same from Feb. 2023 ($45.10 Mil) to May. 2023 ($45.10 Mil) and stayed the same from May. 2023 ($45.10 Mil) to Aug. 2023 ($45.10 Mil).

IntelliPharmaCeutics International's annual additional paid-in capital increased from Nov. 2020 ($44.35 Mil) to Nov. 2021 ($44.63 Mil) and increased from Nov. 2021 ($44.63 Mil) to Nov. 2022 ($45.10 Mil).

IntelliPharmaCeutics International Additional Paid-In Capital Historical Data

The historical data trend for IntelliPharmaCeutics International's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Additional Paid-In Capital Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Additional Paid-In Capital

Get a 7-Day Free Trial

45.11

44.17

44.35

44.63

45.10

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Additional Paid-In Capital	Get a 7-Day Free Trial															44.65	45.10	45.10	45.10	45.10

IntelliPharmaCeutics International Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

IntelliPharmaCeutics International Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.